• Login
    View Item 
    •   SU+ Home
    • Research and Publications
    • Strathmore Business School (SBS)
    • SBS Scholarly Articles
    • View Item
    •   SU+ Home
    • Research and Publications
    • Strathmore Business School (SBS)
    • SBS Scholarly Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Chloramphenicol Pharmacokinetics in African children with severe malaria

    Thumbnail
    View/Open
    Article (98.97Kb)
    Author
    Kokwaro, G.
    Muchohi, Simon N.
    Ogutu, Benhards R.
    Newton, Charles RJC
    Metadata
    Show full item record
    Abstract
     
     
    The objective of this study was to determine if the current dosage regimen for chloramphenicol (CAP) administered to children with severe malaria (SM) for presumptive treatment of concomitant bacterial meningitis achieves steady state plasma CAP concentrations within the reported therapeutic range of 10–25 mg/l. Fifteen children (11 male, 4 female) with a median age of 45 months (range: 10–108 months) and having SM, were administered multiple intravenous doses (25 mg/kg, 6 hourly for 72 h) of chloramphenicol sodium succinate (CAPS) for presumptive treatment of concomitant bacterial meningitis. Blood samples were collected over 72 h, and plasma CAPS, CAP and CSF CAP concentrations determined by high performance liquid chromatography. Average steady state CAP concentrations were approximately 17 mg/l, while mean fraction unbound (0.49) and CSF/plasma concentration ratio (0.65) were comparable to previously reported values in Caucasian children. Clearance was variable (mean=4.3 l/h), and trough plasma concentrations during the first dosing interval were approximately 6 mg/l. Simulations indicated that an initial of loading dose of 40 mg/kg CAPS, followed by a maintenance dose of 25 mg/kg every 6 h would result in trough CAP concentrations of approximately 10 mg/l and peak concentrations <25 mg/l throughout the treatment period. The current dosage regimen for CAP needs to include a loading dose of 40 mg/kg CAPS to rapidly achieve plasma CAP concentrations within the reported therapeutic range.
     
    URI
    http://hdl.handle.net/11071/3857
    Collections
    • SBS Scholarly Articles [54]

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of SU+Communities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV